<DOC>
	<DOCNO>NCT01836068</DOCNO>
	<brief_summary>To find possible HIV-1 patient maintain antiretroviral medication allogeneic bone marrow transplant</brief_summary>
	<brief_title>Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation HIV-1 Individuals</brief_title>
	<detailed_description>Determine feasibility maintain optimal ART HIV-1 infect patient allogeneic hematopoietic stem cell transplant ( HSCT ) . The primary outcome fraction patient maintain form anti-retroviral therapy , include enfuvirtide monotherapy , day 60 post-transplant . If patient unable take oral anti-retroviral medication , able tolerate subcutaneous enfuvirtide monotherapy consider maintenance ART . Failure maintain ART define ≥ 24 hour without anti-retroviral therapy .</detailed_description>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>HIV1 infection , document rapid HIV1 test FDAapproved HIV1 enzyme chemiluminescence immunoassay ( E/CIA ) test kit confirm western blot time prior study entry . Alternatively , two HIV1 RNA value &gt; 200 copies/mL least 24 hour apart perform laboratory CLIA certification , equivalent may use document infection . Patients must ≥ 18 year age . Plan undergo Myeloablative , HLA match partially HLAmismatched ( haploidentical ) , relateddonor bone marrow transplantation include highdose posttransplantation Cy use bone marrow relate donor : Plan undergo Nonmyeloablative , HLA match partially HLAmismatched , relateddonor bone marrow transplantation include highdose posttransplantation Cy use bone marrow relate donor : Patients know history enfuvirtide resistance eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV positive</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Allogeneic BMT</keyword>
	<keyword>BMT</keyword>
</DOC>